Feldan Therapeutics ǀ Feldan Thérapeutiques

Feldan Therapeutics is a clinical-stage biopharmaceutical company based in Quebec City, Canada. Founded in 2008 by François-Thomas Michaud, the company focuses on developing treatments using its proprietary Feldan Shuttle technology, which enables the efficient delivery of therapeutics into cells. This innovative platform is designed to target intracellular proteins while minimizing effects on healthy cells, making it particularly suitable for localized treatments of skin and lung diseases.

Feldan's pipeline includes several promising therapies, such as FLD-103, which is in Phase 1 clinical trials for basal cell carcinoma, and FLD-201, a preclinical program aimed at treating non-cystic fibrosis bronchiectasis. The company also explores natural killer cell therapies for solid tumors. With a dedicated team of experts in various scientific and business fields, Feldan Therapeutics is committed to advancing its innovative solutions in the biopharmaceutical landscape.